Exosomal mutant BRAF as a promising biomarker for monitoring BRAFi therapy Zocco et al. (2020); Detection in lymphatic drainage derived EVs from stage III melanoma patients correlates with risk of relapse García-Silva et al. (2019). Here, BRAF is linked to melanoma.